Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Martek fire fallout

This article was originally published in The Tan Sheet

Executive Summary

Fire at supplier DSM's Belvidere, N.J. ARA manufacturing plant will cause an estimated $5 mil. to $10 mil. loss in sales this quarter, Martek estimates in a May 17 statement. The fire shut down ARA production, which could be discontinued at the facility for a period of weeks. The full impact on the firm's revenues "will be determined once the extent of equipment damage is further assessed." Separately, Martek announced the filing of a universal SEC-shelf registration statement May 21 for debt securities, stock and warrants with a value of up to $200 mil...

You may also be interested in...

Glaxo Mother’s goes subcontinental

GlaxoSmithKline launches Mother's Horlicks in India, a powdered drink mix for pregnant and breast-feeding mothers containing Martek's docosahexaenoic acid (DHA), Martek announces June 24. Mother's Horlicks is a "small part" of the Horlicks line, but Martek believes the product "will help set the stage" for expanded food and beverage applications for other products containing DHA. Martek recorded revenues of $41.9 mil. with earnings of $3.4 mil. in its most recent quarter, with results reflecting inefficiencies in the firm's arachidonic acid (ARA) production and a loss of sales due to a fire at a N.J. manufacturing facility (1"The Tan Sheet" May 24, 2004, In Brief)...

Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand

Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.

No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built

Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts